The U.S. Food and Drug Administration provided Emergency Use Authorization (EUA) for the PerkinElmer Inc.’s New Coronavirus RT-PCR test.

New York will launch a clinical trial using blood plasma from patients who have recovered from COVID-19, the disease caused by the novel coronavirus.